Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Advaccine logo — Advancing Vaccines，Improving Immunotherapeutics

Advaccine

Advancing Vaccines，Improving Immunotherapeutics

Founded 2009 China China 5 employees Private Equity Total: $236.60M Biopharma, Biotechnology +1

General Information

Company Name Advaccine
Founded Year 2009
Location China China
Employees 5
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with Advaccine. To contact Advaccine, visit advaccine.science.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Advaccine compare?

A PDF of Advaccine and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Advaccine soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Advaccine

Advaccine is a biopharmaceutical company founded in 2009 in China, focusing on advancing vaccines and improving immunotherapeutics. The company has a robust pipeline of prophylactic and therapeutic vaccines targeting diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV), and hepatitis B virus (HBV), addressing significant unmet medical needs. Moreover, Advaccine is also developing cancer vaccine candidates, including those for viral-related oncology, neoantigen-based therapeutic vaccines, and tumor-associated antigen therapeutic vaccines. The company recently secured a $6.60M private equity round investment on 05 April 2021, with participation from Matrix Partners China and Hony Capital. With its in-house developed technology platforms and industrial manufacturing capabilities, Advaccine holds promising potential in the biopharma, biotechnology, and pharmaceutical industries. Its dedication to tackling challenging diseases and advancing immunotherapeutics makes it an attractive prospect for investors.

Business keywords: vaccine development, prophylactic vaccines, therapeutic vaccines, SARS-CoV-2, respiratory syncytial virus, hepatitis B virus, cancer vaccines, biotech, drug discovery, unmet medical needs, innovation, immunotherapy, oncology, viral-related oncology, industrial manufacturing

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round $6.60M 2
Matrix Partners China Hony Capital
Matrix Partners China, Hony Capital
05 Apr 2021
Series B CNY200.00M 4
New Alliance Capital Matrix Partners China Star Capital
New Alliance Capital, Matrix Partners China +2
30 Sep 2020
Venture Round CNY30.00M 2
New Alliance Capital Shenzhen Guozhong Venture Capital Management
New Alliance Capital, Shenzhen Guozhong Venture Capital Management
01 Feb 2020
Series A Undisclosed 2
Star Capital Fortune Venture Capital
Star Capital, Fortune Venture Capital
01 Jan 2017

Advaccine Alternatives & Competitors

View All Alternatives
Advaccine vs
Rocketvax AG
Rocketvax AG Switzerland

Implementing cutting-edge science in next-generation vaccine design that will improve people’s lives...

Grant
6 employees
Biotechnology, Health Care
Advaccine vs
Memgen, Inc.
Memgen, Inc. United States

Memgen's Vision: Develop Life-Saving Cancer Immunotherapies

Venture round
7 employees
Biotechnology, Health Care
Advaccine vs
BioVaxys Technology Corp.
BioVaxys Technology Corp. Canada

Antiviral and Anticancer Vaccine Platforms Harnessing the Power of T-Cells

Post-IPO Equity
5 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Advaccine

Advancing Vaccines，Improving Immunotherapeutics
Advaccine was founded in 2009.
Advaccine is headquartered in China.
Advaccine operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on vaccine development, prophylactic vaccines, therapeutic vaccines and SARS-CoV-2.
Advaccine has approximately 5 employees.
Advaccine has completed 4 funding rounds, raising a total of $236.60M. The latest funding stage is Private Equity.
Top alternatives and competitors to Advaccine include Rocketvax AG, Memgen, Inc., BioVaxys Technology Corp., Prazer Therapeutics, Chordia Therapeutics Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Advaccine and Rocketvax AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Advaccine, https://bouncewatch.com/company/advaccine, updated 11 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout